The Missing Infrastructure Behind Radical Lifesaving Innovation

When a chemo prolongs suffering by 5%, the system fights over it like hell. When an intervention prevents a clean disaster, the way a rabies shot does, sanity shows up: it gets used, it stays cheap, and the paperwork evaporates. That difference is not morality. It is incentive geometry, and it will decide whether the coming era of repair medicine becomes a public capability or a private luxury.

This matters because we are entering an era where the right to repair, replace tissues and organs, and preserve function stops being a distant idea and becomes a practical question of access. That future will not be decided by any single breakthrough. It will be decided by what gets measured, what gets paid for, what gets legally permitted, and what can be stress-tested before incentives start bending reality.

You Get What You Test For

Modern medicine uses proxies because it has to. The body is too complex for regulators, clinicians, and payers to wait for perfect ground truth.

The trouble starts when proxies stop being instruments and become objectives.

Anti-aging research illustrates this with unusual clarity. Biomarkers and clocks make messy biology readable. But compression has a cost: once biology is reduced to a single score, the score starts to collect authority it did not earn.

A recent Nature Reviews Genetics review is careful about this. Epigenetic clocks can be powerful, and there are serious statistical and computational issues that constrain interpretation, especially across contexts and cell types. (Nature Reviews Genetics, 2024)

The Clock Is Not the Body

Incentives manufacture outcomes. Biomarkers, composite scores, and aging clocks let you condense a sprawling system into something readable and controllable. Some are excellent instruments. The problem is what happens when the instrument becomes the finish line.

What good looks like is an instrument panel, not a single dial. Mechanistic measures stay in the picture, but they sit beside outcomes that matter in lived reality: fewer hospitalizations, fewer major cardiovascular events, faster recovery after stress, and slower progression into frailty. A metric that can be optimized without improving those outcomes is not a health metric. It is a persuasion metric.

Rewinding a clock, by itself, does not mean much. It means a model’s output moved under intervention. That can be encouraging. It is not the same claim as “the organism now has more remaining life.”

Intervene Immune reported that a growth hormone + DHEA + metformin protocol shifted epigenetic age measures downward over a year. That is interesting as a signal. It is not a proof of life extension, especially when DHEA has a long history as an “anti-aging” supplement and has not shown meaningful benefits on body composition, physical performance, insulin sensitivity, or quality of life in a large randomized trial in older adults. (Aging Cell, 2019; New England Journal of Medicine, 2006)

Harold Katcher and Steve Horvath’s group reported that a young porcine plasma fraction more than halved epigenetic ages across multiple rat tissues. Again: dramatic on the clock. The correct reaction is not “we halved biological age,” but “we moved a particular set of estimators hard, fast, and across tissues,” then ask what the durable functional and survival consequences are. (GeroScience, 2023)

That is the point: once a score becomes the win condition, interventions that are good at winning the score show up quickly, even when the mapping to lifespan is weak or unknown.

Causality Gets Weird Because Bodies Repair Themselves

The body is already trying to heal. Cuts close without our permission. Many infections resolve without treatment. Inflammation rises, falls, and sometimes overshoots. Compensation hides damage until a threshold is crossed. That means the baseline is not “no improvement.” The baseline is an active, messy repair process.

Attributing causality is odd when the default story is “the intervention did it.” Improvements can be regression to the mean, temporary compensation, behavior change, or plain biological momentum. The closer the claimed effect is to “supporting resilience,” the easier it is to buy. Repair medicine needs evaluation regimes that reward things that are hard to fake: functional trajectories, event reductions, durability, and the shape of risk over time, not just a metric moving in the desired direction.

Consider heart failure. A patient can be “stable” right up until one hospitalization. After that, the baseline often changes: lower exercise tolerance, higher risk of re-hospitalization, and a tighter margin for anything else that goes wrong. If an intervention moves a biomarker but does not reduce hospitalizations or improve recovery after stress, it has not preserved function. It has decorated a dashboard.

Body Ownership Is No Longer an Abstract Debate

If people can repair and replace tissues and organs, then body ownership becomes operational policy. Consent, control, benefit-sharing, and boundaries around what is alienable are not side issues. They are the permission layer for the entire field.

In 1951, Henrietta Lacks entered a Baltimore hospital for treatment of cervical cancer. Without her informed consent, doctors collected tumor cells that researchers later found could survive and replicate aggressively in the lab. Those cells, named HeLa, became a workhorse of biomedical science: shipped, shared, and studied around the world for decades. The story stays relevant because the same property that makes HeLa revolutionary, the ability to be replicated endlessly, turns one person’s tissue into a perpetual input for research and commerce. Once that happens, questions about consent and who benefits do not stay philosophical. They return as conflict, including modern litigation and settlements.

We need a field that can hold the question of “who owns the body” without collapsing into slogans, and can also ship workable rules. The Oviedo Convention, adopted by the Council of Europe in 1997, is one of the few binding international treaties that treat biomedical progress as something constrained by human rights, especially informed consent and protection from misuse of the body. It matters here because it shows what “body ownership” looks like when it is translated into enforceable rules rather than post-hoc outrage.

A Case Study in Incentives: PSA Screening and the Surgery Gradient

Healthcare has a recurring pattern: a tool is introduced for one purpose, then gets absorbed into an environment that rewards a different behavior.

Here is a deliberately sharp way to phrase it, because soft phrasing often hides the mechanism: in practice, PSA tests are not used to detect prostate cancer, but to reduce the number of excuses needed to perform unnecessary surgeries.
This is not a claim about individual motives. It is what happens when detection expands faster than our ability to separate indolent disease from dangerous disease, inside an environment that predictably pulls treatment behind diagnosis.

This is pointing at something real: the screening debate was never only about the biology of prostate cancer. It was also about what happens when a test increases diagnoses that may never have harmed the patient, and then the environment routes too many of those diagnoses into high-consequence treatment. The U.S. Preventive Services Task Force recommended against PSA-based screening for all men in 2012, explicitly citing the balance of benefits and harms, including overdiagnosis and overtreatment. A later USPSTF recommendation, published in JAMA, again emphasizes false positives, biopsy complications, overdiagnosis, and treatment-related harms such as incontinence and erectile dysfunction. (USPSTF, 2012; JAMA, 2018)

If incentives are going to be designed on purpose, then incentives need witch trials. Meaning: adversarial testing. Red-teaming. A disciplined attempt to break the proposal by asking, “How would a motivated actor satisfy the letter while violating the spirit, and still claim compliance?”

In practice, endpoints and coverage rules should be attacked the way security teams attack software: assume gaming, try to game it, and make the failure modes explicit before they become the business model.

The Scale of Preventable Loss Is Not Hypothetical

A 2025 research letter in JAMA Health Forum estimated 705,331 excess U.S. deaths in 2023 that would not have occurred if the United States had experienced the age-specific mortality rates of other high-income countries, and 820,396 excess deaths in 2022. (JAMA Health Forum, 2025)

That is the context in which the right to repair becomes a serious topic. The moral energy behind “the right to repair and preserve function” is not aesthetic enhancement. It is the obligation to stop treating avoidable loss as ambient background.

Closing

The mistake is thinking the hard part is choosing the right metric. The hard part is preventing the metric from becoming a loophole. Build adversarial review into endpoints, coverage criteria, and consent frameworks now, and the right to repair and preserve function can become ordinary rather than elite. Skip it, and we will keep mistaking scoreboard movement for lives saved.